Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William H Brissette

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Biochemical and Biophysical Research Communications|August 18, 2009
Analysis of the role of the HIF hydroxylase family members in erythropoiesisTimothy S Fisher, Paul D Lira, Jeffrey L Stock, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 16, 2011
Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulationErin E Matthews, Damien Thévenin, Julia M Rogers, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 18, 2006
Destabilizing role of cathepsin S in murine atherosclerotic plaquesKenneth J Rodgers, Deborah J Watkins, Alastair L Miller, et al.
Biochemical and Biophysical Research Communications|August 18, 2009
Defects in embryonic development of EGLN1/PHD2 knockdown transgenic mice are associated with induction of Igfbp in the placentaTerence R S Ozolins, Timothy S Fisher, Diane M Nadeau, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2008
Molecular features crucial to the activity of pyrimidine benzamide-based thrombopoietin receptor agonistsLawrence A Reiter, Christopher S Jones, William H Brissette, et al.
Transplantation|December 27, 2005
Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primatesDominic C Borie, Michael J Larson, Mona G Flores, et al.
Transplantation|April 9, 2005
Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primatesDominic C Borie, Paul S Changelian, Michael J Larson, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2004
Potent small molecule CCR1 antagonistsJohn C Kath, William H Brissette, Matthew F Brown, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2010
Structure-activity relationships and hepatic safety risks of thiazole agonists of the thrombopoietin receptorAmy S Antipas, Laura C Blumberg, William H Brissette, et al.
The Journal of Biological Chemistry|August 12, 2003
CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseasesRonald P Gladue, Laurie A Tylaska, William H Brissette, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Biochemical and Biophysical Research Communications|August 18, 2009
Analysis of the role of the HIF hydroxylase family members in erythropoiesisTimothy S Fisher, Paul D Lira, Jeffrey L Stock, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 16, 2011
Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulationErin E Matthews, Damien Thévenin, Julia M Rogers, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 18, 2006
Destabilizing role of cathepsin S in murine atherosclerotic plaquesKenneth J Rodgers, Deborah J Watkins, Alastair L Miller, et al.
Biochemical and Biophysical Research Communications|August 18, 2009
Defects in embryonic development of EGLN1/PHD2 knockdown transgenic mice are associated with induction of Igfbp in the placentaTerence R S Ozolins, Timothy S Fisher, Diane M Nadeau, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2008
Molecular features crucial to the activity of pyrimidine benzamide-based thrombopoietin receptor agonistsLawrence A Reiter, Christopher S Jones, William H Brissette, et al.
Transplantation|December 27, 2005
Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primatesDominic C Borie, Michael J Larson, Mona G Flores, et al.
Transplantation|April 9, 2005
Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primatesDominic C Borie, Paul S Changelian, Michael J Larson, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2004
Potent small molecule CCR1 antagonistsJohn C Kath, William H Brissette, Matthew F Brown, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2010
Structure-activity relationships and hepatic safety risks of thiazole agonists of the thrombopoietin receptorAmy S Antipas, Laura C Blumberg, William H Brissette, et al.
The Journal of Biological Chemistry|August 12, 2003
CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseasesRonald P Gladue, Laurie A Tylaska, William H Brissette, et al.
Pageof 2